UBS raised the firm’s price target on CVS Health (CVS) to $96 from $79 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Trump Trade: Trump administration prepares new probe into pharma prices
- Trump admin prepares new probe into U.S. pharma prices, FT says
- Trump Weekly: U.S. threatens China with 100% tariff over rare earth controls
- Trump Trade: Trump says cost of GLP-1 drugs to come down ‘pretty fast’
- CVS Specialty Pharmacy to be ‘core partner’ in TrumpRx fertility program